EP1934252B1 - Procedede synthese de conjugues d'insuline - Google Patents

Procedede synthese de conjugues d'insuline Download PDF

Info

Publication number
EP1934252B1
EP1934252B1 EP05813799.3A EP05813799A EP1934252B1 EP 1934252 B1 EP1934252 B1 EP 1934252B1 EP 05813799 A EP05813799 A EP 05813799A EP 1934252 B1 EP1934252 B1 EP 1934252B1
Authority
EP
European Patent Office
Prior art keywords
insulin
och
precursor
buffer
oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05813799.3A
Other languages
German (de)
English (en)
Other versions
EP1934252A1 (fr
EP1934252A4 (fr
Inventor
Nitesh Dave
Partha Hazra
Anuj Goel
Nita Roy
Anand Khedkar
Harish Iyer
Gautam Krishnan
H. S. Manjunath
Shrikumar Suryanarayan
Govindasamy Manikam
Goldy Sachdev
Mayank Garg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Priority to PL05813799T priority Critical patent/PL1934252T3/pl
Publication of EP1934252A1 publication Critical patent/EP1934252A1/fr
Publication of EP1934252A4 publication Critical patent/EP1934252A4/fr
Application granted granted Critical
Publication of EP1934252B1 publication Critical patent/EP1934252B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Definitions

  • the present invention relates to a process for an insulin-oligomer conjugate of formula insulin-oligomer.
  • the process involves cloning and expression of an precursor IP-F of formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain] and subjecting the expressed biosynthetic precursor to conjugation with an activated oligomer followed by protease treatment and purification to get an active insulin-oligomer conjugate.
  • the ⁇ -cells of the pancreatic islets secrete a single chain precursor of insulin, known as pro-insulin which upon proteolysis results in the biologically active polypeptide insulin.
  • the insulin molecule is a highly conserved across species and generally consists of two chains of amino adds linked by disulfide bonds.
  • the natural human insulin molecule (mw 5,807 Daltons), has A-chain of 21 amino add residues with glycine at the amino terminus; and a B-chain of 30 amino acid residues with phenylalanine at the amino terminus.
  • Insulin may exist as a monomer or may aggregate into a dimer or a hexamer formed from three of the dimers. The monomer has the ability to bind to receptors and is the biologically active form.
  • Insulin polypeptide is the primary hormone responsible for controlling the transport, utilization and storage of glucose in the body.
  • a defect in the carbohydrate metabolism as a result of insufficient production of insulin or reduced sensitivity of the receptor to insulin leads to the biological disorder diabetes.
  • Diabetes impairs the normal ability to use glucose as a result increases blood sugar levels (hyperglycemia).
  • As glucose accumulates in the blood excess levels of sugar are excreted in the urine (glycosuria).
  • Other symptoms of diabetes include increased urinary volume and frequency, thirst, itching, hunger, weight loss, and weakness. Diabetes when left untreated leads to ketosis, followed by acidosis with nausea and vomiting. As the toxic products continue to build up, the patient goes into a diabetic coma, which leads to the patient's death.
  • Type I insulin-dependent diabetes mellitus
  • IDDM insulin-dependent diabetes mellitus
  • IDDM insulin-dependent diabetes mellitus
  • IDDM was formerly referred to as "juvenile onset diabetes.”
  • IDDM insulin is not secreted by the pancreas and must be provided from an external source.
  • Type II or adult-onset diabetes can ordinarily be controlled by diet, although in some advanced cases insulin is required.
  • US 6,200,602 reports a drug delivery composition of insulin for colonic delivery of insulin with an absorption promoter which includes a mixture of fatty acids having 6 to 16 carbon atoms and its salts or a mixture of mono/diglycerides of medium chain fatty acids along with a dispersing agent, in a coating to prevent the release of the insulin and absorption promoter until the tablet, capsule or pellet reaches the proximal colon.
  • an absorption promoter which includes a mixture of fatty acids having 6 to 16 carbon atoms and its salts or a mixture of mono/diglycerides of medium chain fatty acids along with a dispersing agent, in a coating to prevent the release of the insulin and absorption promoter until the tablet, capsule or pellet reaches the proximal colon.
  • insulin Even if insulin survives this enzymatic attack, the biological barriers that must be traversed before insulin can reach its receptors in vivo may limit oral administration of insulin. For example, insulin may possess low membrane permeability, limiting its ability to pass from the lumen into the bloodstream.
  • compositions such as insulin have been conjugated with polydispersed mixtures of polyethylene glycol or polydispersed mixtures of polyethylene glycol containing polymers to provide polydispersed mixtures of drug-oligomer conjugates;
  • US 4,179,337 (Davis et al ) reports conjugating polypeptides such as insulin with various polyethylene glycols such as MPEG-1900 and MPEG-5000 supplied by Union Carbide.
  • US 5,567,422 (Greenwald ) reports the conjugation of biologically active nucleophiles with polyethylene glycols such as m-PEG-OH (Union Carbide), which has a number average molecular weight of 5,000 Daltons.
  • US 6,011,008 reports a method for producing a water-soluble polysaccharide conjugate of an oxidation-sensitive substance comprising activating the polysaccharide to a dialdehyde by periodate oxidation; (b) purifying the dialdehyde from interfering anions and by-products; and (c) coupling the substance to the purified dialdehyde by Schiff base formation to form the conjugate.
  • the conjugate of step (c) is reduced to an amine conjugate by a reducing substance.
  • Insulin was conjugated to oxidized AG (arabinogalactan) via an amine or imine bond by reacting a solution of pure oxidized AG (arabinogalactan) in borate buffer solution at pH 8.9 with insulin at 4°C overnight. The clear solution was dialyzed through a cellulose dialysis and the solution was lyophilized to yield 115 mg of a white solid.
  • the crude reaction mixture is dialyzed or difiltered to remove organic solvents and small molecular weight impurities, exchanged against ammonium acetate buffer and lyophilized; which is further subjected to RP-HPLC equilibrated with 0.5% triethylamine/0.5% phosphoric acid buffer (TEAP A).
  • TEAP A triethylamine/0.5% phosphoric acid buffer
  • the column was eluted with a gradient flow using TEAP A and TEAP B (80% acetonitrile and 20% TEAP A) solvent system.
  • WO-A-2004/083234 discloses methods for synthesizing proinsulin polypeptides that include contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate.
  • Methods of synthesizing proinsulin polypeptide-oligomer conjugates, C-peptide polypeptide-oligomer conjugates and other pro-polypeptide-oligomer conjugates are also provided.
  • WO-A-2007/007345 relates to a process for making an insulin-oligomer conjugate in a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out.
  • P. pastoris only insulin precursor and no unprocessed hyperglycosylated ⁇ -factor pro-leader/insulin precursor fusion protein was secreted from P. pastoris.
  • a spacer peptide in the fusion protein increased the fermentation yield of the insulin precursor in P. pastoris.
  • P. pastoris has a capacity for secretory expression of the insulin precursor that is equal to or better than that of S . cerevisiae.
  • the instant invention facilitates the making of insulin-oligomer conjugate from a specified precursor IP-X of formula Z-[B-Chain]-Q-[A-Chain], where Z is a leader where Z is a leader peptide sequence, B-Chain is B chain of human insulin or its analog, Q is a linker peptide sequence between the A and B chain, A-chain is the A chain of human insulin or its analog.
  • IP-X is conjugated with a specified oligomer at the LysB 29 position on the B-chain and the N-terminus amino acid of the leader peptide Z.
  • the IP-X-oligomer conjugate is then subjected to protease treatment followed by purification to get an active insulin-oligomer conjugate.
  • the starting material is the fermented broth containing the precursor IP-X.
  • the broth containing the IP-X is subjected to a combination of chromatography like ion-exchange, HPLC, RP-HPLC and crystallization to purify the IP-X.
  • the instant invention is a more simplified and economical in the making of an insulin-oligomer conjugate wherein several steps involved in obtaining pure insulin crystals in biologically active form are circumvented e.g, transpeptidation of the insulin precursor and cleaving the insulin precursor to get the active insulin and several chromatographic purification steps e.g., ion-exchange chromatography, HPLC and RP-HPLC to get the pure insulin crystals.
  • steps involved in obtaining pure insulin crystals in biologically active form are circumvented e.g, transpeptidation of the insulin precursor and cleaving the insulin precursor to get the active insulin and several chromatographic purification steps e.g., ion-exchange chromatography, HPLC and RP-HPLC to get the pure insulin crystals.
  • the instant invention relates to a process of manufacturing insulin-oligomer conjugate IN-105 comprising, expressing the IN-105 precursor IP-F of formula G-A-V-R-[B-Chain]R-D-A-D-D-R-[A-Chain], treating IP-F with an activated oligomer which conjugates at the LysB 29 position of the IP-F and at the N-terminus amino acid Gly 1 of the leader peptide GAVR.
  • the IP-F is subjected to conjugation with an oligomer having the general formula CO-(CH 2 ) 2 -(OCH 2 CH 2 ) 3 -OCH 3 .
  • the invention provides a process for the preparation of the insulin-oligomer conjugate IN-105 of formula insulin-CO-CH 2 -CH 2 -(OCH 2 CH 2 ) 3 -OCH 3 , the process comprising:
  • the instant invention involves the use of biosynthetic precursor sequence IP-F of formula G-A-V-R-[B-Chain]-R-D-A-D-D-R-[A-Chain].
  • the leader sequence G-A-V-R used in the present invention does not have any negatively charged amino acids as required for enhanced expression of insulin in yeast as disclosed in the literature.
  • the process of the instant invention is a more simplified and economical in the making of an insulin conjugate wherein several steps of purification to obtain pure insulin in biologically active form are circumvented.
  • the instant invention results in a product with no conjugation on the A chain or C-peptide (RDADDR) of IN-105 precursor IP-F and wherein the conjugation takes place on the B chain (LysB 29 ), and at Gly of the leader chain G-A-V-R which is then subjected to protease treatment to get insulin-oligomer conjugate IN-105.
  • RADDR A chain or C-peptide
  • IP-F represents a insulin-oligomer precursor of formula Z-[B-Chain]-Q-[A-Chain], where Z is a leader peptide sequence GAVR, B-chain is B(1-30) of human insulin, linker peptide Q is a linker peptide sequence RDADDR between the A and B chain, and A-chain is A(1-21) of human insulin.
  • the IP-F of is cloned in-frame with the Mat-alpha signal peptide in the Pichia pastoris expression vector, pPIC9K.
  • Pichia pastoris host strain, GS115 is transformed with the recombinant plasmid to obtain a Pichia clone expressing IPF.
  • the secreted IP-F is treated with trypsin, carboxpeptidase B and N hydroxysuccinimide ester (activated oligomer) to yield IN105.
  • the IN-105 precursor IP-F is secreted by P. pastoris into the culture medium.
  • the broth is centrifuged and cells are separated from the supernatant.
  • There are multiple options available for the capture of the precursor IP-F including Hydrophobic Interaction chromatography and Ion Exchange chromatography.
  • cation exchange chromatography and HIC is used to capture the IP-F.
  • Crystallization of the IN-105 precursor IP-F removes any impurities carried through from the fermentation broth into the SP-Sepharose elution pool, this helps to reduce column fouling at the RP-HPLC-1 stage.
  • Ammonium acetate salt which is used to elute the product from the ion exchange column, is also removed by Crystallization.
  • a pure crystalline precursor also helps in reducing cost in the subsequent conjugation step and increases the efficiency of the reaction.
  • the crystalline form can be frozen and stored which would to be substantially stable for multiple days when stored at -20°C.
  • IN-105 is produced by a reaction wherein IP-F is first conjugated at B 29 Lysine using an activated oligomer to give IP-F-oligomer conjugate.
  • the IP-F-oligomer conjugate is subjected to protease treatment, where the linker-peptide (RDADDR) and the leader sequence (GAVR) are cleaved to get the an active insulin-oligomer conjugate.
  • the two proteases used are trypsin and carboxypeptidase B. As the LysB 29 is blocked by the oligomer, the probability of trypsin cleavage at LysB 29 is minimum.
  • a 2 nd protease (carboxypeptidase B) treatment is done to remove the free basic (Arg) amino acid from the B chain, where one extra Arg is attached with the B-30 (Thr) to get final product IN-105.
  • the two protease treatment is carried out in a single operation at optimum reaction condition where yield was maximized with minimum product related impurities generated.
  • the impurities may be separated from IN-105 e.g., the first RP-HPLC step.
  • the impurities are removed when the first RP is run at low pH and final purification is done at high pH.
  • a low loading and a gradient starting from 20 to 35 was carried out at 15 g/L of resin loading.
  • the first RP-HPLC step gave a purity of .about.93-95%.
  • the final product of IN-105 had a purity to 97-98%.
  • pPIC9K/IP-F plasmid was digested with Bgl II and used to transform electrocompetent cells of P . pastoris GS115 ( his4 ) .
  • Regeneration mix was plated onto YNBD agar (1.34% Yeast Nitrogen Base without amino acids, 2% Dextrose, 2% agar) plates and incubated at 30°C for 48 hours. Colonies were grown in YPD (1% Yeast extract, 2% Peptone, 2% Dextrose) broth in micro titre plates along with appropriate controls.
  • YPD agar 1% Yeast extract, 2% Peptone, 2% Dextrose, 2% agar
  • Geneticin G4108
  • Genomic DNA was made from the selected recombinant Pichia clones using zymolyase enzyme for lysis. PCR was carried out using gene specific primers to confirm the integration of IP-F in the genome.
  • GS115 host strain was used a negative control.
  • the clones were analysed for secretion of IP-F for three days after methanol induction in shake flasks.
  • An HPLC method was used for the analysis using Symmetry C18 column (4.6 x 250 mm, 300 A O , 5 micron, Waters) and Buffers A (0.1 %TFA in water) and B (100 % Acetonitrile). The column is equilibrated with 25% Buffer A prior to sample injection.
  • a programmed gradient is applied at a flow rate of 1 ml/min for the sample estimation : a linear gradient of 25% buffer A to 40 % buffer A is made in the first 15 minutes of the programmed gradient after the sample injection; 40 % Buffer A is maintained for the 15th and 16th minutes of the program; then the concentration of Buffer A is brought back to 25 % by using gradient between 16th to 18th minutes; the concentration of Buffer A is kept constant in the run for the last 5 minutes to equilibrate the column for the next run.
  • a loop full of culture from a single isolated colony grown on seed medium (1% Yeast extract, 0.5 peptone, 2% agar and 20 % dextrose monohydrate) is cultivated in 250 ml flask containing 50 ml BYYG medium (1% Peptone, 2% Yeast extract, 1.34% Yeast nitrogen base, 2% glycerol and 10% 1M phosphate buffer of pH 6.0) at 30+/-1 deg C and 230+/-10 rpm. After 48 ⁇ 50 hrs of incubation the optical density measured at 600 nm reaches 10 +/- 2.
  • the cells were resuspended in to 6 ml of production medium (1% Peptone, 2% Yeast extract, 1.34% Yeast nitrogen base, 0.5% methanol and 10% 1M phosphate buffer of pH 6.0) in 100 ml flask in order to make 50 % w/v cell suspension. Flasks were incubated at 30 deg C. 30 micro L of Methanol was added to all flasks every day from 2nd day. Assay on 4 th day was 0.069 g/L.
  • production medium 1% Peptone, 2% Yeast extract, 1.34% Yeast nitrogen base, 0.5% methanol and 10% 1M phosphate buffer of pH 6.0
  • the seed flasks were prepared by cultivating frozen (-85 °C) cells of Pichia in 250 ml flask containing 50 ml growth medium (1% yeast extract, 2% peptone, 10% 1M phosphate buffer of pH 6.0, 0.67% Yeast nitrogen base and 0.1% glycerol) at 30 +/-1 deg C and 230 +/-10 rpm. After 20-28 hrs of incubation, OD (600nm) reaches 10-12. These cells were further cultivated in 2 L fermentor containing one liter fermentation medium consisting of 4 % glycerol, 0.0093% calcium sulfate, 1.82% potassium sulfate, 1.49% magnesium sulfate, 0.0413% potassium hydroxide.
  • Fermentor was run at 30 deg C and pH of 5.0. The aeration rate was set to 0.1-1.0 wm. Agitation speed was adjusted to maintain the dissolved oxygen above 10%. Biomass was build up to 300-400 g/L by 50% glycerol feeding. Methanol was fed for induction. Assay on day 5 of methanol feeding is 0.76 g/L.
  • IN-105 is prepared from the cell free fermentation broth containing the IN-105 precursor by steps comprising of,
  • IN-105 is prepared from the cell free fermentation broth containing the IN-105 precursor by steps comprising of,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (7)

  1. Procédé de préparation d'un conjugué insuline-oligomère IN-105 de formule insuline-CO-CH2-CH2-(OCH2CH2)3-OCH3, le procédé comprenant :
    i) le clonage et l'expression du précurseur polypeptidique synthétique IP-F possédant SEQ ID NO:2, chez Pichia pastoris ;
    ii) la fermentation du clone Pichia pastoris exprimant l'IPF ;
    iii) l'isolation et la purification de l'IP-F ;
    iv) la conjugaison de l'IP-F avec un dérivé de succinimide C14H23NO8 (Numéro CAS 622 405-78-1) au Lys-B29 de la chaine B dans IP-F pour obtenir le conjugué IP-F-oligomère IP-F-CO-CH2-CH2-(OCH2CH2)3-OCH3 ;
    v) le traitement du conjugué IP-F-oligomère IP-F-CO-CH2-CH2-(OCH2CH2)3-OCH3 avec une protéase pour obtenir le conjugué actif insuline-oligomère insuline-CO-CH2-CH2-(OCH2CH2)3-OCH3.
  2. Procédé selon la revendication 1, dans lequel le précurseur IP-F est isolé à partir du bouillon à l'aide de la chromatographie échangeuse d'ions suivie de la cristallisation.
  3. Procédé selon la revendication 2, dans lequel la cristallisation est effectuée dans du phénol et du ZnCl2.
  4. Procédé selon la revendication 1, 2 ou 3, dans lequel la conjugaison de l'IP-F avec le dérivé de succinimide C14H23NO8 (Numéro CAS 622 405-78-1) est effectuée dans un ou plusieurs solvants choisis parmi le tampon de borate, l'acétonitrile, le DMSO.
  5. Procédé selon la revendication 1 à 4, dans lequel le conjugué IP-F-oligomère IP-F-CO-CH2-CH2-(OCH2CH2)3-OCH3 est en outre sujet à la cristallisation.
  6. Procédé selon l'une quelconques des revendications précédentes, dans lequel la protéase est choisie parmi la trypsine ou la carboxypeptidase B ou un mélange de celles-ci.
  7. Procédé selon l'une quelconques des revendications précédentes, dans lequel le conjugué actif insuline-oligomère insuline-CO-CH2-CH2-(OCH2CH2)3-OCH3 est purifié par CLHP-PI et par cristallisation.
EP05813799.3A 2005-10-13 2005-10-13 Procedede synthese de conjugues d'insuline Active EP1934252B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL05813799T PL1934252T3 (pl) 2005-10-13 2005-10-13 Sposób wytwarzania koniugatów insuliny

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2005/000338 WO2007043059A1 (fr) 2005-10-13 2005-10-13 Procédé de synthèse de conjugués d'insuline

Publications (3)

Publication Number Publication Date
EP1934252A1 EP1934252A1 (fr) 2008-06-25
EP1934252A4 EP1934252A4 (fr) 2010-07-14
EP1934252B1 true EP1934252B1 (fr) 2015-06-24

Family

ID=37942365

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05813799.3A Active EP1934252B1 (fr) 2005-10-13 2005-10-13 Procedede synthese de conjugues d'insuline

Country Status (13)

Country Link
US (1) US8058391B2 (fr)
EP (1) EP1934252B1 (fr)
JP (1) JP5047978B2 (fr)
KR (1) KR101269540B1 (fr)
CN (1) CN101291952B (fr)
BR (1) BRPI0520622B8 (fr)
DK (1) DK1934252T3 (fr)
ES (1) ES2546016T3 (fr)
IL (1) IL190666A (fr)
MX (1) MX2008004674A (fr)
PL (1) PL1934252T3 (fr)
PT (1) PT1934252E (fr)
WO (1) WO2007043059A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
US9617337B2 (en) 2009-10-06 2017-04-11 Daiichi Sankyo Company, Limited Siglec-15 antibodies in treating bone loss-related disease

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11361853B2 (en) 2002-10-29 2022-06-14 Practice Velocity, LLC Method and system for automated medical records processing with telemedicine
WO2007093042A1 (fr) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Séquences polynucléotidiques et polypeptidiques intervenant dans le processus de remodelage osseux
WO2008049711A1 (fr) 2006-10-27 2008-05-02 Novo Nordisk A/S Insuline à peptide ajouté
CN102015762B (zh) * 2008-02-19 2015-03-18 百康有限公司 获得纯化的生物活性异源蛋白的方法
MX2011001408A (es) * 2008-08-07 2011-05-02 Biocon Ltd Proceso para la preparacion de compuestos de insulina.
CA2766571A1 (fr) * 2009-07-09 2011-02-24 Biocon Limited Procede chromatographique base sur un gradient non-lineaire preparatif et ses produits purifies
UY33326A (es) 2010-04-14 2011-12-01 Sanofi Aventis Conjugados de insulina-sirna
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
SE539197C2 (en) * 2015-09-15 2017-05-09 Nida Tech Sweden Ab Positioning system and device comprising an electronic ink display
CA3010566A1 (fr) * 2016-01-23 2017-07-27 Biocon Limited Procede bioanalytique pour analogues d'insuline

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB2051574B (en) 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US6011008A (en) 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
IT1291623B1 (it) 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
JP3406244B2 (ja) * 1999-04-30 2003-05-12 伊藤ハム株式会社 新規な融合蛋白質からの組み換えインスリンの製造方法
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
SI1430082T1 (sl) * 2001-09-07 2010-02-26 Biocon Ltd Postopki za sintetiziranje konjugatov inzulinski polipeptid-oligomer in konjugati proinzulinski polipeptid-oligomer in postopki za njihovo sintetiziranje
WO2004044206A1 (fr) * 2002-11-12 2004-05-27 Ckd Bio Corp. Plasmides exprimant de l'insuline humaine et procede de preparation de l'insuline au moyen de ceux-ci
US7635675B2 (en) 2003-08-13 2009-12-22 Biocon Limited Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
EP1907419B1 (fr) * 2005-07-08 2011-01-26 Biocon Limited Preparation de conjugues d'insuline

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG YAN ET AL: "Human insulin from a precursor overexpressed in the methylotrophic yeast Pichia pastoris and a simple procedure for purifying the expression product", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 73, no. 1, 5 April 2001 (2001-04-05), pages 74 - 79, XP002429621, ISSN: 0006-3592, DOI: 10.1002/1097-0290(20010405)73:1<74::AID-BIT1038>3.0.CO;2-V *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9617337B2 (en) 2009-10-06 2017-04-11 Daiichi Sankyo Company, Limited Siglec-15 antibodies in treating bone loss-related disease
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies

Also Published As

Publication number Publication date
JP5047978B2 (ja) 2012-10-10
EP1934252A1 (fr) 2008-06-25
EP1934252A4 (fr) 2010-07-14
IL190666A0 (en) 2008-11-03
KR20080067625A (ko) 2008-07-21
BRPI0520622B8 (pt) 2021-05-25
BRPI0520622A2 (pt) 2009-05-19
PT1934252E (pt) 2015-10-12
US20110020871A1 (en) 2011-01-27
US8058391B2 (en) 2011-11-15
BRPI0520622B1 (pt) 2021-04-13
PL1934252T3 (pl) 2015-10-30
DK1934252T3 (en) 2015-08-31
WO2007043059A1 (fr) 2007-04-19
CN101291952A (zh) 2008-10-22
KR101269540B1 (ko) 2013-05-30
MX2008004674A (es) 2008-11-12
CN101291952B (zh) 2016-02-03
IL190666A (en) 2014-08-31
JP2009511039A (ja) 2009-03-19
ES2546016T3 (es) 2015-09-17

Similar Documents

Publication Publication Date Title
EP1934252B1 (fr) Procedede synthese de conjugues d&#39;insuline
FI102182B (fi) Menetelmä ihmisen insuliinianalogien valmistamiseksi
TWI433681B (zh) 具有極度延遲時間／作用型態之新穎胰島素衍生物（二）
JP5909478B2 (ja) インスリン化合物の調製方法
EP1907419B1 (fr) Preparation de conjugues d&#39;insuline
CN112584853B (zh) 一种新型门冬胰岛素原的结构和制备门冬胰岛素的方法
CZ290079B6 (cs) Způsob produkce inzulinu a meziprodukt pro tento způsob
KR920008710B1 (ko) 인슐린 유도체의 제조방법
MX2009000275A (es) Metodo para preparar analogos de insulina con extremo de cadena b dibasico.
CN115322250A (zh) 一种司美格鲁肽的合成方法
MX2008000344A (en) Preparation of insulin conjugates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080411

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100611

17Q First examination report despatched

Effective date: 20120208

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150213

RIN1 Information on inventor provided before grant (corrected)

Inventor name: IYER, HARISH

Inventor name: DAVE, NITESH

Inventor name: GOEL, ANUJ

Inventor name: KHEDKAR, ANAND

Inventor name: SACHDEV, GOLDY

Inventor name: SURYANARAYAN, SHRIKUMAR

Inventor name: MANIKAM, GOVINDASAMY

Inventor name: MANJUNATH, H. S.

Inventor name: HAZRA, PARTHA

Inventor name: GARG, MAYANK

Inventor name: ROY, NITA

Inventor name: KRISHNAN, GAUTAM

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 732851

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005046823

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI AND CIE SA, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20150827

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2546016

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150917

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20150827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20150401746

Country of ref document: GR

Effective date: 20150929

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 732851

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150624

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150924

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150624

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151024

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005046823

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602005046823

Country of ref document: DE

Representative=s name: HERNANDEZ, YORCK, DIPL.-ING., DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151013

26N No opposition filed

Effective date: 20160329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20051013

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20210928

Year of fee payment: 17

Ref country code: IT

Payment date: 20210910

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20210929

Year of fee payment: 17

Ref country code: GR

Payment date: 20210914

Year of fee payment: 17

Ref country code: PL

Payment date: 20210910

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20211004

Year of fee payment: 17

Ref country code: ES

Payment date: 20211109

Year of fee payment: 17

Ref country code: DK

Payment date: 20211012

Year of fee payment: 17

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20221031

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20221101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230413

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221013

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20230925

Year of fee payment: 19

Ref country code: GB

Payment date: 20230921

Year of fee payment: 19

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221013

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230921

Year of fee payment: 19

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20231130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221014

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230926

Year of fee payment: 19

Ref country code: CH

Payment date: 20231102

Year of fee payment: 19